Aspen Api

VISIT THE VIRTUAL BOOTH, Contact Details

DIGITAL CONTENT

1 INTERVIEW #SpeakPharma, 7 CORPORATE CONTENT #SupplierSpotlight, 3 COMPANY BIO #AboutSupplier, 1 DATA COMPILATION #PharmaFlow, 89 NEWS #PharmaBuzz

ACTIVE PHARMA INGREDIENTS

117 All APIs, 60 USDMF, 28 CEP/COS, 14 JDMF, 15 KDMF, 62 NDC API, 4 VMF, 90 Listed APIs

DEVELOPMENTS

10 Drugs in Development

10 Drugs in Development

FINISHED DOSAGE FORMULATIONS

1869 FDF Dossiers, 37 FDA Orange Book, 113 Europe, 61 Canada, 315 Australia, 1342 South Africa, 1 Listed Dossiers

KEY PRODUCTS

Azathioprine, Desogestrel, Dihydrotestosterone, Estriol, Etonogestrel, Fentanyl, Fentanyl Citrate, Fentanyl Hydrochloride, Ganirelix, Goserelin Acetate, Lanreotide Acetate, Oxytocin, Segesterone Acetate, Testosterone, Testosterone Cypionate, Testosterone Enanthate, Testosterone Propionate, Testosterone Undecanoate

SERVICES

Analytical, API Manufacturing, API & Drug Product Development

Analytical
- 1 Analytical Method Development
API Manufacturing
API & Drug Product Development
- 8 API Development

KEY SERVICES

Contract Manufacturing for Steroid APIs, CDMO for Small Molecules

EXCIPIENTS

1 All Excipients, 1 USDMF

INSPECTIONS & REGISTRATIONS

25 FDA, 30 EDQM, 6 GDUFA

Xls

Filters

Digital content

Explore the latest content creation from this company

INTERVIEW #SpeakPharma

“Our API is a critical resource that’s managed in an innovative, competitive way”

This week, SpeakPharma interviews David Demailly, API Commercial Director at Aspen API and part of the Aspen Pharma Group, a global specialty and branded pharmaceutical company. Aspen API has nearly 100 years of experience in developing and manufacturing active pharmaceutical ingredients (APIs). Demailly discusses Aspen’s expertise, solutions and sustainability efforts that have led to the success of the company. Tell us about Aspen’s history, its culture and its manufacturing. Aspen API is the cooperative force of Aspen Oss in the Netherlands, Fine Chemicals Corporation in South Africa and Aspen API Inc in Sioux City, Iowa, USA. In 2023, Aspen API will celebrate 100 years of API development and manufacturing. We are a driven and collaborative partner in the development, manufacturing and registration of complex and highly potent active drug ingredients, which are utilized in the production of finished dosage forms. Through our global network of customer relationships, Aspen supplies high-quality APIs that in turn help improve the lives of patients every day. We have a global manufacturing network, with facilities in the Netherlands, South Africa and the USA. We also use a network of partnerships in India and China. This extended network mitigates the concerns around the security of global supply. During the Covid pandemic, we remained focused on the needs of our customers and their patients, ensuring continuity of supply of critical APIs to treat Covid, including the expansion of our capacity for those medications. Our workforce of over 1,200 employees is committed to ensuring continuity of supply of our critical products. Aspen API provides our customers with the highest quality products and brings the most effective solution to each customer. To achieve that goal, we take initiative, we work as a collaborative team, and we innovate. What makes Aspen API’s portfolio special? Commitment to quality, safety, innovation, security of supply, compliance and sustainability is in our organizational DNA. Thanks to our people, we are able to offer more than just APIs to our customers. Our strong portfolio includes 65 high-quality APIs across a broad range of therapeutics and chemical process categories, such as high-potency APIs, peptides, oncology APIs, narcotics, analgesics, botanical extraction APIs and biochemical APIs. We have an active new product development process that utilizes market intelligence, which when coupled with our technical expertise, is able to establish new API products that meet the growing needs of the pharmaceutical industry. We are always on the lookout for new ideas and opportunities. Our customers, as well as the international health authorities, including the US Food and Drug Administration (FDA), the European Directorate for the Quality of Medicines (EDQM), Dutch health authorities and the Pharmaceuticals and Medical Devices Agency (PMDA), have repeatedly confirmed that we are a reliable API provider. Each week, we welcome (virtual) inspection teams to our sites, and take pride in each successful inspection. With 300 active Drug Master Files worldwide, we comply with the highest global standards and have comprehensive experience in dealing with regulatory authorities worldwide. How does Aspen API view the collaboration with its customers? We strongly believe in the chemistry of collaboration, at all stages. We work together as partners. Whether the project involves a new chemical entity or a process for (re-)designing an (intermediate) API, we work from the development phase to the commercial implementation stage. Fostering close collaborative relationships with our customers and utilizing our broad technical expertise and long industry experience, we strive to not only understand our customers’ needs, but also to contribute proactively in discussing more effective, efficient and sustainable solutions to their manufacturing requirements. Is sustainability important to Aspen API? Sustainability is a critical building block for the future at Aspen API. Our aim is to minimize our carbon footprint and be a leader in sustainable API manufacturing. Wherever possible, we use green technology and green solvents in our chemical processes. We provide a safe and healthy workplace for our employees, and offer fair pay, excellent education and equal opportunities. While assessing the impact of our environmental, social and corporate governance, we consider our entire supply chain. We are actively involved with various organizations, including Ecovadis, the Carbon Disclosure Project, Ecodesk and the Pharmaceutical Supply Chain Initiative. Can you throw some light on your green solutions? Our technical team has developed a patented method for green and large-scale manufacturing of peptides in a solution called Green Continuous Liquid Phase Peptide Synthesis (Green Continuous-LPPSTM). This method combines the advantages of the classical solution-phase synthesis with the solid-phase approach and is characterized by the fact that intermediates are not isolated. This enables a highly efficient synthesis method that is easy to scale-up and yields products of reproducible high purity. In another example, we have developed an enzymatic route towards a hormone API, through which we use 72 percent less water, five percent less solvent and 26 percent less reactor time compared to the current non-enzymatic and first-generation route. How is your CDMO contributing towards innovation? Our development team is committed towards incorporating innovation and green technology into our clients’ projects. Our close connections with educational institutes and innovation companies, such as the Health Valley Netherlands — the biggest Dutch life sciences and health innovation network — enables us to build a strong foundation for sustainable innovation. What ambition does Aspen API pursue? Our efforts provide products that make the lives of people around the world better. It is our duty to develop safe, innovative and sustainable technologies to strengthen our position in the API business. How do you adapt to the changing business environment? We continuously strive to improve our performance. We demonstrated this during the challenging Covid-19 pandemic, when we continued production and even increased our volumes. Within Aspen, we have a program to organize our work structurally towards our goal of sustainable success. We are also working on new innovative technologies to meet the future needs of the market. When we consider the entire supply chain of pharmaceutical products, API is the crucial beginning and the most critical part of any drug product. Currently, we see a high dependency on countries outside of Europe for key starting materials, components and building blocks for manufacturing vital drug products. The last several years have highlighted the vulnerability of critical manufacturing to supply chain disruptions. The manufacturing of critical APIs in other regions can increase exposure to manufacturing practices that harm the environment. Despite these challenges and constraints, Aspen API has emerged as a major leader in the change to transform, rebuild and position API manufacturing as a critical resource to be managed in an innovative and competitive way. At Aspen, an API is truly more than just an API.

Impressions: 2850

CORPORATE CONTENT #SupplierSpotlight

Product List 2023

Open PDF

Upload

Corporate Presentation

GMP Certificate 2023

Green Answer to Peptide Synthesis

Open PDF

Upload

Your Personal API Partner

Open PDF

Upload

Green Continuous Liquid Phase Peptide Synthesis (GC-LPPS)

Sustainable APIs Manufacturing 2022

COMPANY BIO #AboutSupplier

Overview of high potency APIs or HPAPI contract manufacturing services & more on Aspen API's CDMO services for cytotoxic HPAPIs on PharmaCompass.

Overview of high potency APIs or HPAPI contract manufacturing services & more on Aspen API's CDMO services for cytotoxic HPAPIs on PharmaCompass.Q1. What is a highly potent API (HPAPI)?Highly potent active pharmaceutical ingredient (HPAPI) is a compound that elicits a biological response at a much smaller dose, such as a daily therapeutic dose of <10 mg. High potency drugs have the ability to bind selectively at low doses to specific receptors or inhibit specific enzymes as part of cancer or hormonal therapies.High-potency APIs (HPAPIs) require multi-step processes or semi-synthesis along with special handling requirements due to toxicity. HPAPI development and production require specialized considerations in facility design, equipment, operation and process safety to achieve the requisite level of containment. It also presents major handling challenges for innovators and manufacturing companies.High-potency APIs (HPAPIs) are becoming increasingly popular and companies are now looking for flexible containment solutions to help address their needs. However, if the current HPAPI development continues to show more efficacy, high potent API is likely to become one of the most dominant areas in the industry. High potency API (HPAPI) is prominent in oncology research and hence represents an increasingly significant share of the pharmaceutical drug pipeline.Because a growing number of pharmaceutical products contain highly potent active pharmaceutical ingredients (HPAPI) , demand for the production of HPAPIs has increased. Estimates suggest the global HPAPI market will register a strong growth over the next 5-10 years. In addition to cancer, highly potent API (HPAPI) is being used in hormonal imbalance drugs, cardiovascular drugs, central nervous system drugs and musculoskeletal drugs.The challenges in HPAPI manufacturing have also increased, along with investments, in terms of specialized containment areas and procedures to prevent personnel and environmental exposure. A pharmaceutical CDMO has the capability to offer highly potent small molecule development services and HPAPI Contract Manufacturing Services.Integrated CDMOs have capabilities to offer both production & development services for highly potent APIs (HPAPIs), and to scale-up for HPAPI (highly potent API) development from lab quantities to large-scale volumes. The main advantage of outsourcing HPAPI contract manufacturing services is that it eliminates the need to invest in costly containment infrastructure that can also be difficult to engineer, install and maintain and it can offer HPAPIs, ADCs, highly potent small molecule development services along with manufacturing.Q2. How are the different containment challenges addressed for high-potency APIs (HPAPIs)?HPAPI can be a small-molecule, a biologic, or a hybrid of two molecules, such as an antibody-drug conjugate that links a cytotoxic small molecule to a monoclonal antibody. The cytotoxic nature of highly potent APIs presents significant challenges in terms of safe handling and containment during process scale-up and development, clinical and large-scale production of highly potent APIs (HPAPIs). Hence, HPAPIs require heavy investments for the implementation of specialized containment facilities.Additionally, the cGMP manufacturing of high-potency active pharmaceutical ingredients (HPAPIs) requires an isolated environment that is equipped with isolators and cleanrooms. Working with an experienced pharmaceutical outsourcing organization such as a CMO or CDMO for contract manufacturing of highly potent compounds can help eliminate challenges like investing in expensive infrastructure and the cost of training staff for the production of a highly potent API (HPAPI). Such outsourcing organizations can also offer highly potent intermediates and active pharmaceutical ingredients, ADCs, biologics, large molecule, highly potent small molecule development services along with other contract manufacturing services.HPAPI containment challenges can be handled through the following ways: A manufacturer of HPAPIs should consider several areas in order to safely manage high potency active pharmaceutical ingredient (HPAPI) processes. For successful HPAPI (highly potent API) development, extensive knowledge and experienced staff are required. Relevant training should be provided to the staff. The training should also feature in-depth information on every step of the handling process, equipment use and unit operations. Employee exposure to high potent active pharmaceutical ingredients (HPAPIs) is typically the primary concern for manufacturers. As such, it is essential to put a thorough cleaning program in place to avoid contaminating surfaces. If an undesired event occurs, manufacturers of highly potent intermediates and active pharmaceutical ingredients should have a response plan to work from, indicating appropriate reaction from employees to an unplanned incident. Highly potent active pharmaceutical ingredients (HPAPIs) have a specific occupational exposure limit (OEL) that must be kept in mind to ensure safe handling, as there is a selective process in choosing the most appropriate containment strategy. An occupational physician should work closely with the committee, regulatory authorities and any relevant health and safety bodies. Inadequate containment of high potent API (HPAPI) can decrease product yields or cause cross-contamination of the final product. One of the largest areas for consideration is equipment. All HPAPI handling and development systems must be tested and verified to meet the necessary isolation requirements while developing and manufacturing high potent active pharmaceutical ingredients (HPAPI). The capability of equipment, systems and procedures to contain and isolate materials under expected operating conditions must be verified as it is a critical component of the overall HPAPI handling and development program. There must be a close evaluation of the compound for potential toxicity, potency and hazards while developing and manufacturing high potent active pharmaceutical ingredients (HPAPI). By applying rigorous engineering controls within the process scale-up and development, high-quality high potent active pharmaceutical ingredients (HPAPIs) can be produced without adverse effects. Specialized considerations in facility design, equipment, operation and process scale-up and development as well as safety are needed to achieve the desired level of containment of high potency API (HPAPI) and drug products. It is necessary to carry out a careful assessment of the hazards posed by each product, reagent and intermediate involved in the synthesis before cGMP manufacturing. To identify the exposure potential, factors including the quantity of material to be handled, the percentage of high potent active pharmaceutical ingredients (HPAPI) and any excipient components, along with the task duration should be considered.Q3. How do contract development and manufacturing organizations (CDMOs) help in the production of HPAPIs?High potency active pharmaceutical ingredient (HPAPI) is a growing area for pharmaceutical manufacturers. Around a third of all drugs in the pharmaceutical pipeline are categorized as high potency active pharmaceutical ingredients (HPAPIs). However, HPAPIs have strict handling requirements that require high capital investment and specialized personnel to develop. Producing ADC, which requires conjugation of a small molecule to a large biomolecule, is even more challenging.Highly potent compounds present numerous challenges in terms of preventing cross-contamination during developing and manufacturing high potent active pharmaceutical ingredients (HPAPIs). As a result, many HPAPI investigators turn to contract development and manufacturing organizations (CDMOs) and CMOs who have the facilities, equipment and personnel in place to take their projects through HPAPI development and manufacturing.While many CDMOs have made significant investments in their highly potent API (HPAPI) capabilities over the last two decades to provide reliable support throughout all project stages, including process scale-up and development, clinical and commercial cGMP manufacturing. A pharmaceutical CMO or CDMO has capabilities such as isolator design, laboratory design and containment practices that are critical for safe HPAPI and cytotoxic drugs manufacturing.Most HPAPIs in clinical development are outsourced to contract development and manufacturing organizations (CDMOs) that have the necessary process expertise, qualified facilities for the production of highly potent intermediates and active pharmaceutical ingredients.Points to consider while choosing a CDMO for HPAPI development and Manufacturing: Any CDMO considered as an HPAPI production partner should have experience in the field and a long track record of successfully manufacturing and handling potent compounds, including highly potent intermediates and active pharmaceutical ingredients. There should be clear evidence of regulatory expertise and a positive compliance history. The appropriate containment strategy should be selected for HPAPI (highly potent API) development and manufacturing based on scale. CDMO facilities should include cGMP compliant isolator systems (OEL 0.1 µg/m³) for high-potent raw materials, intermediates and APIs. The ability of a CDMO to support projects for developing and manufacturing high potent active pharmaceutical ingredients (HPAPIs) through commercialization as well as extensive analytical capabilities are quite important. These factors are indicators of long-term commitment to HPAPI production. CDMO facilities should be designed with containment strategies based primarily on engineering controls, such as equipment and procedures, ventilation, chemical contaminants, etc. and administrative solutions (processes and PPE) as secondary measures. Also, rigorous safety, health and environmental (SHE) practices, along with Occupational Exposure Band (OEB) and Occupational Exposure Limit (OEL) based controls, need to be established to protect workers, materials, machines and the environment.Q4. What HPAPI manufacturing services does Aspen API offer?Aspen API is a contract development & manufacturing organization (CDMO) that provides development, upscaling and commercial manufacturing for complex high potency API (HPAPI), peptide APIs, oncology APIs, cytotoxic APIs, along with narcotics and other established APIs. Aspen API has over 58 high-quality APIs available, ranging from high potency, oncology, peptides, narcotics, analgesics and botanical extraction to biochemical APIs.At Aspen API, CDMO or CMO API projects are in excellent hands. Aspen API can add value to the client's projects and collaborate with the client to ensure success. It has a century-long history in development, upscaling and commercially manufacturing complex high potency APIs (HPAPIs), oncology APIs, peptides, along with narcotics and other established APIs. Whether the project is for a New Chemical Entity (NCE) or a process for (re-)designing (intermediate) API, Aspen API is the perfect partner to manage projects - from the development phase to the commercial implementation. Aspen API adds expertise, innovation, compliance, registration and partnership to the client's projects.Aspen API's facilities are successfully inspected and approved by regulatory authorities such as US FDA, EDQM, PMDA and others. It has expertise in manufacturing high potency API (HPAPI) and oncology APIs. Supported by a robust quality system, Aspen API produces high-quality products, which are manufactured in compliance with cGMP, ICH and safety, health and environmental (SHE) regulations.At both Aspen Oss and Fine Chemicals Corporation, high potent APIs are produced in units with OEB 4 and 5 classifications. Aspen API has a long history of working with Occupational Exposure Limit (OEL) levels, from as low as 0.01 µg/m³. Its heritage in manufacturing complex highly potent active pharmaceutical ingredients (HPAPIs) has enabled Aspen API to establish world class systems and procedures for safe HPAPI handling and development. At Fine Chemicals Corporation, high potent active pharmaceutical ingredients (HPAPI) and cytotoxic product manufacturing is carried out in a dedicated purpose-built facility.Manufacturing capabilities Manufacturing under full cGMP Batches ranging from 1 kg to 500 kg active pharmaceutical ingredient (API) Commercial manufacturing ranging from 100 to 10.000 liters Best-in-class cleaning procedures Isolator technology for micronization and milling of Occupational Exposure Band (OEB) 4 and 5 compounds for HPAPI Manufacturing Grade D clean room manufacturing for weighing and dispensing Integration in processes In-house safety, health and environmental (SHE) specialists with expert knowledge Well-trained staff and best-in-class safety protocols Safety assessments using calorimetry on processes, intermediates and active pharmaceutical ingredients (APIs) All intermediates and active pharmaceutical ingredients (APIs) on site assigned to Occupational Exposure Band (OEB) category ISO14001 and ISO 45001 certified

Impressions: 1626

DATA COMPILATION #PharmaFlow

CDMO Activity Tracker: Novo’s parent buys Catalent for US$ 16.5 bn; Fujifilm, Merck KGaA, Axplora expand capabilities

During the first half (H1) of 2024, the global contract development and manufacturing organization (CDMO) landscape was driven by the escalating demand for complex drug development and manufacturing.With the industry grappling with constantly evolving therapeutic modalities, CDMOs are racing to invest in cutting-edge technologies and infrastructure to meet the growing needs of pharmaceutical and biotech companies.Some of the key players in the CDMO space are Catalent, EUROAPI, Lonza, Axplora, Thermo Fisher, SEQENS, Samsung Biologics, Fujifilm Diosynth Biotechnologies, Quotient Sciences, Famar, LGM Pharma, Veranova, and Evonik.View CDMO Activity Tracker for H1 2024 (Free Excel Available) Novo’s parent buys Catalent for US$ 16.5 bn; Bora, Lonza, Siegfried expand US footprintDuring H1 2024, several European and Asian drugmakers expanded their footprints in the US. In February, Novo Nordisk’s parent company, the Novo Nordisk Foundation, announced the acquisition of Catalent through its investment arm Novo Holdings for US$ 16.5 billion. Novo Holdings plans to sell three of Catalent’s “fill-finish” sites to Novo Nordisk for US$ 11 billion. The deal is expected to allow the Danish drugmaker “to serve significantly more people living with diabetes and obesity,” a company statement said.Taiwan-headquartered Bora Pharmaceuticals forged ahead with its expansion plans in the US market by acquiring Minnesota-based generics manufacturer Upsher-Smith Laboratories. Emergent BioSolutions said it is selling its Maryland facility to an affiliate of Bora. This site in Camden is part of its CDMO, Emergent Bioservices, and offers clinical and commercial non-viral aseptic fill/finish services on four fill lines, including lyophilization, formulation development, and support services.Swiss drugmaker Lonza has agreed to acquire Genentech’s manufacturing facility in California, US, from Roche for US$ 1.2 billion in cash. The site, located in the city of Vacaville, is one of the largest biologics manufacturing facilities in the world by volume.Lonza also launched an artificial intelligence-driven route design technology for choosing the optimal synthetic pathway to manufacture novel APIs.Switzerland’s Siegfried is acquiring a Wisconsin (US)-based CDMO that specializes in early-phase development and manufacturing services from Curia Global to strengthen its capabilities in North America. Siegfried will further develop the site into its North American Siegfried Acceleration Hub for early-phase CDMO services.View CDMO Activity Tracker for H1 2024 (Free Excel Available) Merck Millipore, SK Bioscience lead CGT boom; Fujifilm, Axplora, expand CDMO capabilitiesThe burgeoning field of cell and gene therapies (CGTs) is driving significant investments in CDMOs. CGTs saw considerable deal-making too. Merck KGaA agreed to buy Wisconsin-based Mirus Bio for US$ 600 million. Mirus Bio is a specialist in the development and commercialization of transfection reagents that are used to help introduce genetic material into cells. These reagents play a key role in the production of viral vectors for CGTs.Similarly, South Korea’s SK Bioscience acquired a 60 percent stake in IDT Biologika GmbH for KRW 339 billion (US$ 244 million). IDT Biologika is a 104-year-old German company that ranks among the top 10 vaccine producers in the world.CDMOs are also expanding their capabilities in order to lead innovation for their pharmaceutical partners. Fujifilm Diosynth Biotechnologies is investing US$ 1.2 billion in its large-scale cell culture CDMO business to further expand its end-to-end bio-manufacturing facility in North Carolina, bringing the total investment in the facility to over US$ 3.2 billion. Similarly, Merck KGaA owned MilliporeSigma made its biggest investment in the Asia-Pacific region in March when it invested € 300 million (US$ 327 million) in a new bioprocessing production center in Daejeon, South Korea.German CDMO giant Axplora is investing € 8 million (US$ 8.73 million) to expand capacity for antibody drug conjugate (ADC) payload manufacturing at its Le Mans site in France. Catalent completed upgrades to its capsule filling capabilities of dry powders for inhalation to handle potent drugs at its Boston facility. This now positions Catalent as the CDMO with the largest GMP capacity for capsule spray-dried and carrier-based inhaled powders.LGM Pharma increased its Analytical Testing Services (ATS) by 50 percent with a US$ 2 million investment and introduced new suppository manufacturing capabilities to its CDMO portfolio. Minakem has invested in a new production unit in Montreal, Canada, for steroid APIs.View CDMO Activity Tracker for H1 2024 (Free Excel Available) EUROAPI kicks off four-year sweeping plan; LegoChem partners Samsung Biologics for ADC programSanofi’s spinoff EUROAPI marked 2024 as a “transition year”, setting in motion its Focus-27 plan for profitable growth in the future. The sweeping four-year plan includes a streamlined value-added portfolio focused on highly differentiated and profitable APIs, and a CDMO focused on late-stage and high-value complex small molecules and tides supported by unique technological platforms. The leading French small molecules player signed a five-year collaboration with Ireland’s Priothera wherein EUROAPI will develop and industrialize the manufacturing process of an innovative, complex molecule for blood cancers – mocravimod. The project will be carried out at EUROAPI’s site in Budapest, which is its center of excellence for complex chemistry.South Korea’s CDMO powerhouse Samsung Biologics has partnered LegoChem Biosciences and will provide antibody development and drug substance manufacturing services as a part of LegoChem’s ADC program designed to treat solid tumors. LegoChem aims to submit an investigational new drug application to the US Food and Drug Administration (FDA) in the first half of 2025. Aurigene and Vipergen have joined forces to offer DNA-encoded library (DEL) screening for drug discovery. By combining Aurigene’s drug discovery capabilities with Vipergen’s DEL screening technologies, they seek to create a powerful tool that can quickly test over a billion small-molecule compounds against different disease targets. Dr. Reddy’s Laboratories’ company Aurigene also inaugurated its biologics facility spread across 70,000 square feet.Chinese biotech startup Pleryon is collaborating with France’s SEQENS, a leader in specialty ingredients, to develop and manufacture the former’s lead candidate, an innovative polymer to treat osteoarthritis. Famar is collaborating with Lavipharm and will serve as the contract manufacturer for the latter’s recently added analgesic pharmaceutical products — Lonarid N and Lonalgal.View CDMO Activity Tracker for H1 2024 (Free Excel Available) Our view Key trends observed in H1 2024 include a surge in investments for fill-finish facilities, a growing emphasis on cell and gene therapies, and advancements in ADC manufacturing. With the proliferation of these new classes of drugs, the CDMO space has been rapidly changing in recent years. In the future, the integration of digital technologies, such as AI and automation, will be a key differentiator for CDMOs looking to optimize their operations and accelerate drug development timelines.

Impressions: 2333

NEWS #PharmaBuzz

Nieké van Gils, Jr. scientist at Aspen API on international women’s day.

07 Mar 2024

// PRESS RELEASE

Gold Medal for Aspen API in EcoVadis Evaluation

31 Oct 2023

// PRESS RELEASE

Fine Chemicals Corporation facility in Cape Town, South Africa was inspected by the PMDA.

31 Oct 2023

// PRESS RELEASE

Get to know the Aspen API sales managers! Interview with Ivette Cosme – Sales manager Aspen API

05 Jul 2023

// PRESS RELEASE

Get to know the Aspen API sales managers! Interview with Blandine Le Tallec – Sales manager Aspen API

21 Jun 2023

// PRESS RELEASE

Get to know the Aspen API sales managers! Interview with Norman van Zoggel – Senior sales manager Aspen API

13 Jun 2023

// PRESS RELEASE

Contact Aspen Api and get a quotation

Aspen Api is a supplier offers 109 products (APIs, Excipients or Intermediates).

Find a price of Budesonide bulk with DMF, CEP, JDMF offered by Aspen Api

Find a price of Desogestrel bulk with DMF, CEP, JDMF offered by Aspen Api

Find a price of Estradiol bulk with DMF, CEP, JDMF offered by Aspen Api

Find a price of Estriol bulk with DMF, CEP, JDMF offered by Aspen Api

Find a price of Ethinyl Estradiol bulk with DMF, CEP, JDMF offered by Aspen Api

Find a price of Leuprolide Acetate bulk with DMF, CEP, JDMF offered by Aspen Api

Find a price of Mirtazapine bulk with DMF, CEP, JDMF offered by Aspen Api

Find a price of Norethisterone bulk with DMF, CEP, JDMF offered by Aspen Api

Find a price of Norethisterone Acetate bulk with DMF, CEP, JDMF offered by Aspen Api

Find a price of Progesterone bulk with DMF, CEP, JDMF offered by Aspen Api

Find a price of Rocuronium Bromide bulk with DMF, CEP, JDMF offered by Aspen Api

Find a price of Asenapine Maleate bulk with DMF, JDMF offered by Aspen Api

Find a price of Azathioprine bulk with DMF, CEP offered by Aspen Api

Find a price of Desmopressin Acetate bulk with DMF, CEP offered by Aspen Api

Find a price of Estradiol Valerate bulk with DMF, CEP offered by Aspen Api

Find a price of Gonadorelin Acetate bulk with DMF, CEP offered by Aspen Api

Find a price of Naloxone Hydrochloride bulk with DMF, CEP offered by Aspen Api

Find a price of Oxytocin bulk with DMF, CEP offered by Aspen Api

Find a price of Ropivacaine Hydrochloride bulk with DMF, CEP offered by Aspen Api

Find a price of Scopolamine bulk with DMF, CEP offered by Aspen Api

Find a price of Testosterone bulk with DMF, CEP offered by Aspen Api

Find a price of Baclofen bulk with DMF offered by Aspen Api

Find a price of Benztropine bulk with DMF offered by Aspen Api

Find a price of Budesonide bulk with JDMF offered by Aspen Api

Find a price of Buprenorphine Hydrochloride bulk with DMF offered by Aspen Api

Find a price of Conjugated Estrogens bulk with DMF offered by Aspen Api

Find a price of Estradiol Acetate bulk with DMF offered by Aspen Api

Find a price of Estriol bulk with CEP offered by Aspen Api

Find a price of Ethynodiol Diacetate bulk with DMF offered by Aspen Api

Find a price of Etonogestrel bulk with DMF offered by Aspen Api

Find a price of Fentanyl bulk with CEP offered by Aspen Api

Find a price of Fentanyl Citrate bulk with CEP offered by Aspen Api

Find a price of Fluphenazine bulk with DMF offered by Aspen Api

Find a price of Fluphenazine Decanoate bulk with DMF offered by Aspen Api

Find a price of Fondaparinux Sodium bulk with DMF offered by Aspen Api

Find a price of Ganirelix bulk with DMF offered by Aspen Api

Find a price of Gonadorelin Acetate bulk with DMF offered by Aspen Api

Find a price of Heparin Sodium bulk with DMF offered by Aspen Api

Find a price of Human Chorionic Gonadotropin bulk with DMF offered by Aspen Api

Find a price of Hydroxyprogesterone Caproate bulk with DMF offered by Aspen Api

Find a price of Leuprolide Acetate bulk with CEP offered by Aspen Api

Find a price of Levalbuterol Hydrochloride bulk with DMF offered by Aspen Api

Find a price of Methazolamide bulk with DMF offered by Aspen Api

Find a price of Methyl Testosterone bulk with DMF offered by Aspen Api

Find a price of Naltrexone Hydrochloride bulk with DMF offered by Aspen Api

Find a price of Nandrolone Decanoate bulk with DMF offered by Aspen Api

Find a price of Penbutolol bulk with DMF offered by Aspen Api

Find a price of Prednisolone bulk with DMF offered by Aspen Api

Find a price of Remifentanil bulk with DMF offered by Aspen Api

Find a price of Ropivacaine Hydrochloride bulk with DMF offered by Aspen Api

Find a price of Testosterone Cypionate bulk with DMF offered by Aspen Api

Find a price of Testosterone Enanthate bulk with DMF offered by Aspen Api

Find a price of Testosterone Undecanoate bulk with DMF offered by Aspen Api

Find a price of Tetracosactide bulk with DMF offered by Aspen Api

Find a price of Thiothixene bulk with DMF offered by Aspen Api

Find a price of Tibolone bulk with CEP offered by Aspen Api

Find a price of Vecuronium Bromide bulk with DMF offered by Aspen Api

Find a price of Vincristine Sulfate bulk with DMF offered by Aspen Api

Find a price of Danaparoid sodium bulk offered by Aspen Api

Find a price of Eptifibatide bulk offered by Aspen Api

Find a price of Heparin Sodium bulk offered by Aspen Api

Find a price of Rimexolone bulk offered by Aspen Api

Find a price of Afamelanotide bulk offered by Aspen Api

Find a price of Angiotensin II bulk offered by Aspen Api

Find a price of Avapritinib bulk offered by Aspen Api

Find a price of Bremelanotide Acetate bulk offered by Aspen Api

Find a price of Brexanolone bulk offered by Aspen Api

Find a price of Capmatinib bulk offered by Aspen Api

Find a price of Cidofovir bulk offered by Aspen Api

Find a price of Codeine bulk offered by Aspen Api

Find a price of Codeine Phosphate bulk offered by Aspen Api

Find a price of Difelikefalin bulk offered by Aspen Api

Find a price of Dihydrotestosterone bulk offered by Aspen Api

Find a price of Dydrogesterone bulk offered by Aspen Api

Find a price of Elagolix Sodium bulk offered by Aspen Api

Find a price of Fentanyl Hydrochloride bulk offered by Aspen Api

Find a price of Ganaxolone bulk offered by Aspen Api

Find a price of Goserelin Acetate bulk offered by Aspen Api

Find a price of Hyoscine Butyl Bromide bulk offered by Aspen Api

Find a price of Lanreotide Acetate bulk offered by Aspen Api

Find a price of Linzagolix bulk offered by Aspen Api

Find a price of Lixisenatide bulk offered by Aspen Api

Find a price of Lorlatinib bulk offered by Aspen Api

Find a price of Lynestrenol bulk offered by Aspen Api

Find a price of Morphine Hydrochloride bulk offered by Aspen Api

Find a price of Morphine Sulfate bulk offered by Aspen Api

Find a price of Morphine Tartrate bulk offered by Aspen Api

Find a price of Nomegestrol Acetate bulk offered by Aspen Api

Find a price of Norelgestromin bulk offered by Aspen Api

Find a price of Norgestimate bulk offered by Aspen Api

Find a price of Noscapine bulk offered by Aspen Api

Find a price of Pacritinib bulk offered by Aspen Api

Find a price of Pasireotide Pamoate bulk offered by Aspen Api

Find a price of Pegcetacoplan bulk offered by Aspen Api

Find a price of Pholcodine bulk offered by Aspen Api

Find a price of Plecanatide bulk offered by Aspen Api

Find a price of Relugolix bulk offered by Aspen Api

Find a price of Segesterone Acetate bulk offered by Aspen Api

Find a price of Teduglutide bulk offered by Aspen Api

Find a price of Testosterone Acetate bulk offered by Aspen Api

Find a price of Testosterone Decanoate bulk offered by Aspen Api

Find a price of Testosterone Dodecanoate bulk offered by Aspen Api

Find a price of Testosterone Isocaproate bulk offered by Aspen Api

Find a price of Testosterone Phenylpropionate bulk offered by Aspen Api

Find a price of Testosterone Propionate bulk offered by Aspen Api

Find a price of Thioridazine Hydrochloride bulk offered by Aspen Api

Find a price of Vinblastine Sulfate bulk offered by Aspen Api

Find a price of Voclosporin bulk offered by Aspen Api

Find a price of Vosoritide bulk offered by Aspen Api

Company Digital Content of Aspen Api

Aspen API

VISIT THE VIRTUAL BOOTH

Review portfolio & marketing content

CONTACT DETAILS

Google Map, LinkedIn, Emails...

EVENTS

Webinars & Exhibitions

PRESENTATION(s)

VIDEO(s)

DIGITAL CONTENT

1 INTERVIEW #SpeakPharma

7 CORPORATE CONTENT #SupplierSpotlight

3 COMPANY BIO #AboutSupplier

1 DATA COMPILATION #PharmaFlow

89 NEWS #PharmaBuzz

ACTIVE PHARMA INGREDIENTS

DEVELOPMENTS

10 Drugs in Development

FINISHED DOSAGE FORMULATIONS

KEY PRODUCTS

SERVICES

Analytical

API Manufacturing

API & Drug Product Development

KEY SERVICES

EXCIPIENTS

INSPECTIONS & REGISTRATIONS

Filters